Phase Ib RCT in recurrent high-grade glioma: adding subcutaneous IFNγ to intratumoral Delta-24-RGD did not significantly increase long-term survivors vs Delta-24-RGD alone (27 randomised, 37 treated). Post hoc, immune markers distinguished long-term survivors.
Secondary analysisn = 37
Ene et al. Systemic Immune Correlates of Long-term Survival after Delta-24-RGD Based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET)